Lupin launches Sevelamer Hydrochloride tablets in US

02 Mar 2022 Evaluate

Lupin has launched Sevelamer Hydrochloride Tablets, 800 mg, in US market. The company has launched the product after having received approval from the US Food and Drug Administration (USFDA). The product will be manufactured at Lupin's facility in Nagpur, India.

Sevelamer Hydrochloride Tablets, 800 mg is a generic equivalent of Renagele Tablets, 800 mg of Genzyme Corporation. Sevelamer Hydrochloride Tablets, 800 mg (RLD: Renagel) had estimated annual sales of $75 million in the U.S. (IQVIA MAT December 2021).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2198.25 12.00 (0.55%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.